Skip to main
RLAY
RLAY logo

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 57%
Buy 36%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics Inc is demonstrating a positive outlook as it advances its clinical-stage pipeline, particularly with RLY-2608, which shows a notable overall response rate (ORR) of 38.7% and improved median progression-free survival (mPFS) of 9.2 months, extending to 11.4 months among patients with kinase mutations. The recent data suggests that RLY-2608 offers better tolerability and dose intensity, resulting in longer durability for breast cancer patients, thereby enhancing its therapeutic potential. Additionally, the FDA approval of Truqap (capivasertib) + Faslodex reinforces the validity of targeting the PI3K/AKT pathway in treating advanced breast cancer, showcasing the significant advancements in Relay Therapeutics' precision medicine approach.

Bears say

Relay Therapeutics Inc. is projected to experience a widening net loss, anticipated at $2.15 per share for the full year 2025, indicating ongoing financial challenges for the company. There are numerous significant risks affecting the company's outlook, including the potential for negative clinical data, slower-than-expected development timelines, and setbacks in both earlier and later-stage trials, which could hinder approval and commercialization of its drug candidates. This backdrop of increasing losses combined with competitive landscape risks and potential dilution adds to the negative outlook on the company's financial health and future viability in the market.

RLAY has been analyzed by 14 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 36% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 14 analysts, RLAY has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.